Galapagos New SpinCo CEO appointed, Paul Stoffels to retire as Galapagos CEO
Galapagos announced two executive leadership updates including i) the appointment of Henry Gosebruch as CEO of the SpinCo following the previously announced company split, while ii) Paul Stoffels has informed the board of his intent to retire from his role as CEO upon appointment of a successor, and to remain as non-executive chair of the Galapagos board. We are encouraged by the appointment of a well experienced executive to lead SpinCo, while Paul Stoffels' decision to retire as CEO comes as a bit of surprise to us, and while a specific reason was not provided, a replacement CEO is expected in the next 12 months. Having said that, we continue to believe in the potential of de-centralised CAR-Ts to address some of the limitations of centralised CAR-Ts, and reiterate our Buy rating and € 37 TP.Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.